Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

Blood

Volumn 117, Issue 22, 2011, Pages 5827-5834

  Piekarz, Richard L ^a   Frye, Robin ^b   Prince, H Miles ^c   Kirschbaum, Mark H ^d   Zain, Jasmine ^d   Allen, Steven L ^e   Jaffe, Elaine S ^b   Ling, Alexander ^f   Turner, Maria ^b   Peer, Cody J ^b   Figg, William D ^b   Steinberg, Seth M ^b   Smith, Sonali ^g   Joske, David ^h   Lewis, Ian ⁱ   Hutchins, Laura ^j   Craig, Michael ^k   Fojo, A Tito ^b   Wright, John J ^a   Bates, Susan E ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h SIR CHARLES GAIRDNER HOSPITAL   (Australia)

ⁱ ROYAL ADELAIDE HOSPITAL   (Australia)

^j UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^k WEST VIRGINIA UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ROMIDEPSIN;

ADULT; AGED; ANEMIA; ANGIOIMMUNOBLASTIC LYMPHADENOPATHY; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; CLINICAL ARTICLE; CONSTIPATION; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DYSGEUSIA; ENTEROPATHY ASSOCIATED T CELL LYMPHOMA; EPSTEIN BARR VIRUS INFECTION; FATIGUE; FEMALE; FEVER; GRANULOCYTOPENIA; HEART VENTRICLE TACHYCARDIA; HEPATITIS B; HERPES ZOSTER; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERURICEMIA; HYPOALBUMINEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFECTION; LARGE CELL LYMPHOMA; LEUKOPENIA; LUNG INFECTION; LYMPHOPROLIFERATIVE DISEASE; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIPHERAL T CELL LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; SIDE EFFECT; SKIN INFECTION; STEM CELL TRANSPLANTATION; T WAVE; THROMBOCYTOPENIA; THRUSH; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING;

EID: 79952977561     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-10-312603     Document Type: Article

References (35)

1. Richon VM, Webb Y, Merger R, et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci U S A. 1996;93(12):5705-5708. (Pubitemid 26191313)
2. Archer SY, Meng SF, Shei A, Hodin RA. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci U S A. 1998;95(12):6791-6796.
3. Sandor V, Senderowicz A, Mertins S, et al. P21-dependent G(1) arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer. 2000;83(6):817-825.
4. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst. 2000;92(15):1210-1216. (Pubitemid 30627729)
5. Peart MJ, Smyth GK, van Laar RK, et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A. 2005; 102(10):3697-3702. (Pubitemid 40354674)
6. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell. 2003;4(1):13-18. (Pubitemid 36904157)
7. Ueda H, Nakajima H, Hori Y, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo). 1994;47(3):301-310.
8. Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res. 1998;241(1):126-133. (Pubitemid 28366586)
9. Sandor V, Bakke S, Robey RW, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res. 2002;8(3):718-728. (Pubitemid 34742100)
10. Marshall JL, Rizvi N, Kauh J, et al. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol. 2002;2(6):325-332. (Pubitemid 35265981)
11. Piekarz RL, Robey R, Sandor V, et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: A case report. Blood. 2001;98(9):2865-2868.
12. Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009;27(32):5410-5417.
13. Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28(29):4485-4491.
14. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(21):3109-3115. (Pubitemid 47218059)
15. Ellis L, Pan Y, Smyth GK, et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res. 2008;14(14):4500-4510.
16. Jaffe ES, Harris NL, Stein H, Vardiman, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001.
17. Vose JM, Neumann M, Harris ME, Int TCLP. International peripheral T-cell and natural killer/ T-cell lymphoma study: Pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124-4130.
18. O'Connor OA, Horwitz S, Hamlin P, et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol. 2009;27(26):4357-4364.
19. Piekarz RL, Frye AR, Wright JJ, et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res. 2006;12(12):3762-3773. (Pubitemid 44000258)
20. Shiraga T, Tozuka Z, Ishimura R, Kawamura A, Kagayama A. Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes. Biol Pharm Bull. 2005;28(1):124-129. (Pubitemid 40879796)
21. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244.
22. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205-216.
23. Chen XH, Gardner ER, Figg WD. Determination of the cyclic depsipeptide FK228 in human and mouse plasma by liquid chromatography with mass-spectrometric detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;865(1-2):153- 158.
24. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1-10. (Pubitemid 19099520)
25. Ritchie D, Piekarz RL, Blombery P, et al. Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report. Haematologica. 2009;94(11):1618-1622.
26. Piekarz R, Bates S. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des. 2004;10(19):2289- 2298. (Pubitemid 38855037)
27. Subramanian S, Bates SE, Wright JJ, Espinoza-Delgado I, Piekarz RL. Clinical toxicities of histone deacetylase inhibitors. Pharmaceuticals. 2010;3(9):2751-2767.
28. Woo S, Gardner ER, Chen XH, et al. Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res. 2009;15(4):1496-1503.
29. Bates SE, Zhan ZR, Steadman K, et al. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br J Haematol. 2010;148(2):256-267.
30. Cabell C, Bates S, Piekarz R, et al. Systematic assessment of potential cardiac effects of the novel histone deacetylase (HDAC) inhibitor romidepsin. Blood. 2009;114(22):1428-1429.
31. Bates SE, Rosing DR, Fojo T, Piekarz RL. Challenges of evaluating the cardiac effects of anti-cancer agents. Clin Cancer Res. 2006;12(13):3871-3874. (Pubitemid 44078067)
32. Malik S, Liu K, Qiang X, et al. Folotyn. (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: food and drug administration drug approval summary. Clin Cancer Res. 2010;16(20):4921-4927.
33. Prince HM, Bishton MJ, Harrison SJ. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res. 2009;15(12):3958-3969.
34. Pohlman B, Advani R, Duvic M, et al. Final results of a phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma. Blood (ASH Annual Meeting Abstracts). 2009;114(22): Abstract 920.
35. Piekarz RL, Bates SE. Epigenetic Modifiers: Basic understanding and clinical development. Clin Cancer Res. 2009;15(12):3918-3926.